 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...4567891011121314...1516» |
- | Edurant (rilpivirine) / J&J
Journal: Near full-length genomic characterization of a novel HIV-1 B/C recombinant form identified in Guangdong Province, China. (Pubmed Central) - Sep 10, 2021
The drug resistance profile indicates high-level resistance against efavirenz and rilpivirine. This study identified a recombinant between the main circulating strains, indicating a more complicated trend of the HIV-1 epidemic in Guangdong, China.
- | clarithromycin / Generic mfg.
Journal: Applications of a grid-based CYP3A4 Template system to understand the interacting mechanisms of large-size ligands; part 4 of CYP3A4 Template study. (Pubmed Central) - Aug 26, 2021
Ligand entry from left side of Template is also suggested from macrolide interactions. Broadened applicability of the refined CYP3A4 Template were assured with experiments with various large-size ligands.
- | Edurant (rilpivirine) / J&J
Enrollment change, Trial termination: RISE: A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (clinicaltrials.gov) - Aug 20, 2021
P3, N=58, Terminated, Sponsor: Johnson & Johnson Pte Ltd
Broadened applicability of the refined CYP3A4 Template were assured with experiments with various large-size ligands. N=100 --> 58 | Recruiting --> Terminated; High SF rate (less treatment-na
- | Journal: Changes in functional connectivity in people with HIV switching antiretroviral therapy. (Pubmed Central) - Aug 20, 2021
Changes in fMRI are evident in PWH without perceived neuropsychiatric complaints switching cART. fMRI may be a useful tool in assisting to elucidate the underlying pathogenic mechanisms of cART-related neuropsychiatric effects.
- | Edurant (rilpivirine) / J&J
Journal: Genetic characteristics of CRF12_BF first identified in Guangdong Province, China. (Pubmed Central) - Aug 20, 2021
Additionally, this CRF12_BF strain was confirmed to contain the non-nucleoside reverse transcriptase inhibitor mutation E138A associated with potential low-level resistance against efavirenz and low-level resistance against rilpivirine by the Stanford University HIV Drug Resistance Database program. The analysed sequence data in this study will provide more information on the HIV epidemic in China.
- | Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Journal: Metabolism of Long-Acting Rilpivirine Following Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076). (Pubmed Central) - Aug 20, 2021
P2
A total of 8 missense variants of UGT1A4 were detected, whereas 2 variants were detected for UGT1A1; however, these variants did not appear to account for the observed interindividual variability in metabolite levels. These findings provide insight into the metabolism of long-acting RPV and contribute to overall understanding of metabolism following oral dosing versus injection.
- | Pifeltro (doravirine) / Merck (MSD), doravirine/islatravir (MK-8591A) / Merck (MSD), islatravir (MK-8591) / Merck (MSD)
Preclinical, Journal: Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir. (Pubmed Central) - Aug 12, 2021
Doravirine showed a more robust resistance profile compared with other NNRTIs. The long intracellular half-life of islatravir and delayed acquisition of resistance in dual selections provide an opportunity for long-acting treatment options.
- || Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Review, Journal: Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis. (Pubmed Central) - Aug 10, 2021
For virologic suppression at 48 weeks, odds ratios (95% credible intervals) were 0.6 (0.43, 0.82) for EFV+ tenofovir disoproxil fumarate (TDF)+emtricitabine (FTC) versus DTG+ abacavir+ lamivudine (3TC) and 0.52 (0.36, 0.75) for EFV+TDF+FTC vs. DTG+TDF+FTC/3TC...Outcomes associated with death were unsuitable for network meta-analysis due to low event rates. 3-drug regimens containing INI demonstrate better efficacy and safety than those containing RPV or EFV.
- |||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Open label, Randomized clinical trial to evaluate switching from dual regimens to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients Studio in aperto, randomizzato, per valutare il passaggio da una terapia duplice ad una terapia con E/C/F/TAF in pazienti adulti HIV positivi con carica virale negativa. (EUDRACT) - Aug 10, 2021
P3, N=100, Ongoing, Sponsor: OSPEDALE SAN RAFFAELE
- | Journal: LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV. (Pubmed Central) - Aug 8, 2021
GS-6207 is a novel HIV capsid inhibitor that is injected subcutaneously every 3 months...These approaches appear to be especially attractive for patients complaining of pill fatigue, and for those experiencing HIV-associated stigma. As these formulations are shown to be safe, well-tolerated, and economical, they are likely to gain broader appeal.
- | Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
Journal: Small Molecules of Natural Origin as Potential Anti-HIV Agents: A Computational Approach. (Pubmed Central) - Aug 7, 2021
Three natural products (ZINC37538901, ZINC38321654, and ZINC67912677) containing oxan and oxolan rings with hydroxyl substituents and one (ZINC2103242) having 3,6,7,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-1,4-dione core exhibited comparable profiles to etravirine and doravirine, with ZINC2103242 being the most promising anti-HIV candidate in terms of drug metabolism and safety profile. These findings may open new avenues to guide the rational design of novel HIV-1 NNRTIs.
- | Edurant (rilpivirine) / J&J
Journal: Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs. (Pubmed Central) - Aug 7, 2021
EuS nanoprobes parallel the uptake and biodistribution of NRPV. These data support their use in modeling NRPV delivery to improve treatment strategies.
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Biodegradable Polymeric Solid Implants for Ultra-Long-Acting Delivery of Single or Multiple Antiretroviral Drugs. (Pubmed Central) - Aug 5, 2021
While biodegradable and do not require removal, these PSIs can safely be removed to terminate the treatment if required. The versatility of this technology makes it attractive as an ULA drug delivery platform for HIV and various therapeutic applications.
- | Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. (Pubmed Central) - Aug 1, 2021
The larger size of the NNRTI binding pocket in the mutant enzyme facilitates a better fit for the active compounds, while stacking interactions with Phe227 and Pro236 contribute to inhibitor binding. Mass spectrometry data were consistent with the covalent modification of the RT, although off-target reactivity constitutes a major limitation for further development of the described inhibitors.
- Edurant (rilpivirine) / J&J
THE ANTIRETROVIRAL DRUG RILPIVIRINE DIMINISHES IP-10 / CXCL10 EXPRESSION: RELEVANCE IN THE CONTEXT OF LIVER DISEASE () - Jul 31, 2021 - Abstract #AEEH2021AEEH_253;
- Edurant (rilpivirine) / J&J
THE HEPATOPROTECTIVE ROLE OF THE ANTIRETROVIRAL DRUG RILPIVIRINE IS ASSOCIATED WITH ALTERED AUTOPHAGY IN IN VITRO AND IN VIVO MODELS OF LIVER FIBROSIS () - Jul 31, 2021 - Abstract #AEEH2021AEEH_249;
- Edurant (rilpivirine) / J&J
INHIBITION OF CCL2 / CCR2 AXIS BY RILPIVIRINE CONTRIBUTES TO ITS ANTI-INFLAMMATORY EFFECTS IN A MODEL OF NON-ALCOHOLIC FATTY LIVER DISEASE () - Jul 31, 2021 - Abstract #AEEH2021AEEH_248;
- | Edurant (rilpivirine) / J&J
Trial completion, Enrollment change: Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction (clinicaltrials.gov) - Jul 30, 2021
P=N/A, N=33, Completed, Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
Mass spectrometry data were consistent with the covalent modification of the RT, although off-target reactivity constitutes a major limitation for further development of the described inhibitors. Not yet recruiting --> Completed | N=60 --> 33
- | Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial). (Pubmed Central) - Jul 28, 2021
Despite low/undetectable PI/NNRTI plasma concentrations on OFF period, patients maintained undetectable viral load. Mechanistic explanation should be investigated.
- || PK/PD data, Retrospective data, Review, Journal: Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials. (Pubmed Central) - Jul 27, 2021
CAB-LA and RPV-LA have promising safety and pharmacokinetic profiles. The preventive efficacy of these agents is being evaluated in Phase 3 trials.
- Edurant (rilpivirine) / J&J
[VIRTUAL] THE ANTIRETROVIRAL DRUG RILPIVIRINE DIMINISHES IP-10/CXCL10 EXPRESSION: RELEVANCE IN THE CONTEXT OF LIVER DISEASE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4739;
Clinically relevant concentrations of the antiretroviral drug RPV diminish CXCL10 protein expression, an effect observed both in vivo and in vitro. This action may be of relevance for the molecular mechanisms of hepatoprotection exerted by RPV.
- Edurant (rilpivirine) / J&J
[VIRTUAL] THE ANTIRETROVIRAL DRUG RILPIVIRINE DIMINISHES IP-10/CXCL10 EXPRESSION: RELEVANCE IN THE CONTEXT OF LIVER DISEASE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2559;
Clinically relevant concentrations of the antiretroviral drug RPV diminish CXCL10 protein expression, an effect observed both in vivo and in vitro. This action may be of relevance for the molecular mechanisms of hepatoprotection exerted by RPV.
- Edurant (rilpivirine) / J&J
[VIRTUAL] THE ANTIRETROVIRAL DRUG RILPIVIRINE DIMINISHES IP-10/CXCL10 EXPRESSION: RELEVANCE IN THE CONTEXT OF LIVER DISEASE (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_728;
Clinically relevant concentrations of the antiretroviral drug RPV diminish CXCL10 protein expression, an effect observed both in vivo and in vitro. This action may be of relevance for the molecular mechanisms of hepatoprotection exerted by RPV.
- | Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection. (Pubmed Central) - Jul 14, 2021
This action may be of relevance for the molecular mechanisms of hepatoprotection exerted by RPV. No abstract available
- || efavirenz / Generic mfg.
Clinical, Journal: High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients. (Pubmed Central) - Jul 8, 2021
High efavirenz exposure is associated with worse cognitive functioning compared with patients with therapeutic concentrations. Plasma Nfl is not a suitable biomarker to measure cognitive damage in this group.
- | Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Retrospective data, Journal: Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. (Pubmed Central) - Jul 7, 2021
No difference in the cardiovascular risk after 1 year from the switch to these STRs were observed. PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults. (Pubmed Central) - Jul 3, 2021
RPV is effective, safe and considerably more tolerable than compared to NNRTI or boosted PI in ABC/3TC-containing regimens for treatment-naïve patients. It offers an affordable and attractive option, especially in resource-limited settings.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France. (Pubmed Central) - Jul 2, 2021
It offers an affordable and attractive option, especially in resource-limited settings. Rilpivirine-containing regimens yielded high rates of viral suppression in most participants, while it was ineffective when used outside the marketing authorization in naive participants.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Usefulness of Therapeutic Drug Monitoring of Rilpivirine and relationship with virologic response and resistance in a cohort of naive and pre-treated HIV-infected patients. (Pubmed Central) - Jul 1, 2021
This study shows the impact of rilpivrine plasma trough concentration on both virological response and the emergence of rilpivirine mutations. Moreover, our results suggest that a higher target of rilpivirine trough concentration could be proposed in clinical practice.
- || Tybost (cobicistat) / Gilead, Prezista (darunavir) / J&J
Clinical, Journal, Head-to-Head: Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). (Pubmed Central) - Jun 26, 2021
P4
Moreover, our results suggest that a higher target of rilpivirine trough concentration could be proposed in clinical practice. Once-daily rilpivirine plus cobicistat-boosted darunavir is an effective 2DR that combines a high virological efficacy with a potential to avoid major NRTI toxicities.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? (Pubmed Central) - Jun 26, 2021
In virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes.
- || Clinical, Journal: Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China. (Pubmed Central) - Jun 26, 2021
We did not observe a higher risk of adverse pregnancy outcomes. High frequencies of DRMs and resistance were observed among CRF55_01B-infected patients failing ART in Guangdong, and interventions may be considered to minimize ecological contributions to ART.
- | Pifeltro (doravirine) / Merck (MSD)
Preclinical, Journal: In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. (Pubmed Central) - Jun 26, 2021
Substantial cross-resistance to doravirine was detected in NNRTI-resistant viruses harbouring complex mutational patterns, even in the absence of major IAS-USA doravirine RAMs. Therefore, based on the simple IAS-USA reference list, doravirine resistance may be underestimated in viruses harbouring multiple NNRTI mutations.
- | Rescriptor (delavirdine mesylate) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II). (Pubmed Central) - Jun 22, 2021
All the results obtained from different databases are compiled, interpreted and five molecules were subjected to molecular dynamic studies to further confirm the prediction and identified hit molecules for in vitro screening as potential NNRTIs. Communicated by Ramaswamy H. Sarma.
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Journal: Understanding of cabotegravir degradation through isolation and characterization of key degradation products and kinetic studies. (Pubmed Central) - Jun 22, 2021
Moreover, degradation pathway to predominant oxidation degradation product is proposed based on the adduct of cabotegravir and peroxide species, which was identified by LC-HRMS analysis. This is the first report to the best of our knowledge that describes characterized cabotegravir forced degradation impurities and provides insights into its degradation pathways.
- | Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment open: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - Jun 8, 2021
P1/2, N=155, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This is the first report to the best of our knowledge that describes characterized cabotegravir forced degradation impurities and provides insights into its degradation pathways. Active, not recruiting --> Recruiting
- [VIRTUAL] Impact of baseline NNRTI pretreatment resistance mutations on risk of virologic failure of RPV-based dual therapies () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1271;
RPV-based dual therapies were effective simplification strategies in this cohort. Detectable HIV-RNA and the presence of any NNRTI PDRMs at the time of switch were significantly associated with virologic failure.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1049;
This fabrication process is simple, scalable, and does not require high heat, high pressure or use of high volumes of organic solvents. The fabricated PSIs are highly tunable, ultra-LA, and contain high drug loading to provide translatable to human drug doses for HIV PrEP/ART.
- [VIRTUAL] HIV minority resistance variants partially explain genotypic-phenotypic discordance () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_995;
Discordance, mostly represented by genotypic DR overestimation, was partially explained by NGS minority DR variants. This suggests that minority DR variants might help refine genotypic interpretation algorithms to avoid inappropriate choice of drugs; but also, existence of alternative explanations.
- [VIRTUAL] Weight gain following the single substitution of TDF by TAF in people living with HIV (PLWH) in the French Dat'AIDS cohort () - May 27, 2021 - Abstract #IASHIV2021IAS_HIV_793;
Retrospective multi-center study including virologically suppressed (<200 copies/mL) adult PLWH switching from TDF/emtricitabine/rilpivirine (TDF/FTC/RPV) to TAF/FTC/RPV or from TDF/FTC/elvitegravir/cobistat (TDF/FTC/EVG/c) to TAF/FTC/EVG/c between 01/2004 and 12/2019 in the French Datu2019AIDS cohort. In our study, a mild but significant weight gain was observed in virologically suppressed PLWH switching from TDF to TAF
- || Edurant (rilpivirine) / J&J, Vemlidy (tenofovir alafenamide) / Gilead
Clinical, Journal: Grado de satisfacción y conocimiento de pacientes positivos para HIV ante el cambio de tenofovir a tenofovir-alafenamida en tratamientos con emtricitabina y rilpivirina (Pubmed Central) - May 21, 2021
Objective: To evaluate the degree of knowledge and satisfaction in patients who had their antiretroviral regimen switched from rilpivirine (RPV)/emtricitabine (FTC)/TDF to RPV/FTC/TAF.Conclusiones. En general, los pacientes se mostraron satisfechos con el cambio de medicación y conocían la posología del medicamento y las ventajas de la tenofovir-alafenamida frente al tenofovir, pero no sus posibles efectos adversos.
- | Edurant (rilpivirine) / J&J
Journal: Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking. (Pubmed Central) - May 15, 2021
The intact drug crystals were easily detected in CD4 T cells and macrophages, the natural viral target cells, by flow cytometry and ultraperformance liquid chromatography tandem mass spectrometry. We conclude that AIE can be harnessed to monitor cell biodistribution of selective antiretroviral drug nanocrystals.
- | Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - May 6, 2021
P1/2, N=155, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
We conclude that AIE can be harnessed to monitor cell biodistribution of selective antiretroviral drug nanocrystals. Trial completion date: Apr 2026 --> Jul 2025 | Trial primary completion date: May 2022 --> Dec 2022
- || bictegravir (GS-9883) / Gilead
Clinical, Journal: Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. (Pubmed Central) - Apr 28, 2021
Weight gain is ubiquitous in clinical trials of ART initiation, and is multifactorial in nature, with demographic factors, HIV-related factors, and the composition of ART regimens contributing. The mechanisms by which certain ART agents differentially contribute to weight gain are unknown.
- | Journal: Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. (Pubmed Central) - Apr 28, 2021
In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared to dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.
- | Edurant (rilpivirine) / J&J
Journal: Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. (Pubmed Central) - Apr 22, 2021
Herein, we created multimodal rilpivirine (RPV) lutetium labeled bismuth sulfide nanorods (LuBSNRs) then evaluated their structure, morphology, configuration, chemical composition, biological responses and adverse reactions...The latter was seen within the marginal zones of spleen. These data, taken together, support the use of LuBSNRs as theranostic probes as a rapid assessment tool for PK LA ARV measurements.
- || Edurant (rilpivirine) / J&J
Also, E138K and M184I/V mutations are mutually compensatory and may explain the frequent occurrence of E138K/M184I after the virologic failure of rilpivirine-, lamivudine-, and emtricitabine-containing regimens. (Twitter) - Apr 18, 2021
- | Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence? (Pubmed Central) - Apr 17, 2021
Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.
- || Edurant (rilpivirine) / J&J
Yes! PPIs + Rilpivirine Simva/lovastatin + PIs/boosters, FTR Steroids (including inh fluticasone) + PIs/boosters QTc prolonging agents + RPV, FTR (Twitter) - Apr 11, 2021
- || Pifeltro (doravirine) / Merck (MSD)
Clinical, Review, Journal: Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. (Pubmed Central) - Apr 10, 2021
Overall, minimal cross-resistance across NNRTIs was observed for doravirine, as well as limited development of doravirine-related resistance. These data should assist clinicians in further understanding the resistance profile of doravirine, so appropriate treatment decisions can be made for their patients.